Don't Miss a Beat: ESC Congress 2023 Preview & SELECT Reaction

For years, the European Society of Cardiology (ESC) annual congress has stood as the most prominent international meeting in the field of cardiology.

In recent years, it has begun to take on the role of the foremost cardiology, regardless of location, and it appears the ESC is hoping this trend will continue as it prepares for the ESC Congress 2023, which will be conducted in Amsterdam and virtually from August 25-28, 2023. With thousands of unique abstracts and more than half a dozen hot line sessions planned for presentation, the meeting is expected to bring forth the latest advances across the spectrum of disciplines in cardiology.

In this episode of Don’t Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, codirector of the Center for Implementation Science at Brigham and Women’s Hospital, and Stephen Greene, MD, advanced heart failure specialist at the Duke Clinical Research Institute, sit down for a discussion surrounding the meeting itself and take a deep dive into 3 late-breaking trials from ESC Congress 2023: STEP HFpEF, HEART-FID, and the QUEST trials. Also included in this episode is a brief conversation on the topline results of the SELECT trial and what it means for management of cardiometabolic illness.

STEP-HFpEF

• Being presented by Mikhail Kosiborod, MD, of St. Luke’s Mid America Heart Institute, in Hot Line Session 1 on August 25 at 11:15 CEST.
• Double-blind, multicenter, prospective, randomized, placebo-controlled study to assess the effects of semaglutide against placebo in people living with heart failure and obesity.
• Primary outcomes of interest included the change in body weight from the start to the end of the study and compare heart failure symptoms in those using semaglutide compared to placebo therapy.

HEART-FID

• Being presented by Robert Mentz, MD, of Duke Clinical Research Institute, in Hot Line Session 2 on August 26 at 9:14 CEST.
• Double-blind, multicenter, prospective, randomized, placebo-controlled study to assess the effects of IV FCM compared to placebo in people with heart failure and iron deficiency.
• Primary outcomes of interest are 12-month rate of death, hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test distance.

QUEST

• Being presented by Xinli Li, of the First Affiliated Hospital of Nanjing Medical University, in Hot Line Session 1 on August 25 at 8:30 CEST.
• Double-blind, multicenter, parallel-group, randomized, placebo-controlled, event-driven study examining use of qiliqiangxin, a traditional Chinese medicine capsule, approved in China for the treatment of chronic heart failure.
• Primary outcome of interest was a composite cardiovascular death and re-hospitalization due to the worsening of heart failure.

Disclosures:

Vaduganathan reports having received funding for consulting or research grants from Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others.

Greene reports having received funds for consulting or research grants from Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.